Asset Details
Do you wish to reserve the book?
Roxithromycin attenuates bleomycin-induced pulmonary fibrosis by targeting senescent cells
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Roxithromycin attenuates bleomycin-induced pulmonary fibrosis by targeting senescent cells
Do you wish to request the book?
Roxithromycin attenuates bleomycin-induced pulmonary fibrosis by targeting senescent cells
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Roxithromycin attenuates bleomycin-induced pulmonary fibrosis by targeting senescent cells
2021
Overview
Idiopathic pulmonary fibrosis (IPF) is an aging‐associated disease with a poor prognosis. Emerging evidence has revealed that targeting senescent cells may be a potential treatment for IPF. In this study, we aimed to explore whether roxithromycin (RXM) can improve lung fibrosis by targeting senescent cells. First, we confirmed the ability of RXM to selectively kill senescent cells by inducing apoptosis and inhibiting the expression of senescence‐associated secretory phenotype (SASP) factors, suggesting the potential role of RXM as a “senolytic” and “senomorphic” drug. Next, we observed that TGF-β- and senescent cell-induced lung fibroblast activation was inhibited by RXM treatment, which prompted us to further investigate its effect in vivo. In a mouse model of bleomycin (BLM)-induced pulmonary fibrosis, RXM was shown to attenuate lung injury, inflammation, and fibrosis. Furthermore, the senescent phenotype of lung tissues induced by BLM was significantly diminished after RXM administration, indicating the potential of RXM as an antifibrotic and antisenescent agent. Interestingly, NADPH oxidase 4 (NOX4), implicated in lung fibrosis and cell senescence, was shown to be inhibited by RXM treatments. The antifibroblast activation and antisenescent effects of RXM were abolished in NOX4 knockdown cells, demonstrating that RXM may ameliorate BLM-induced pulmonary fibrosis by targeting senescent cells mediated by the NOX4 pathway. Collectively, these data demonstrated that RXM may be a potential clinical agent for IPF and further supported the notion that targeting cellular senescence is a promising treatment for progressive age-related disease.
Publisher
Springer Singapore,Nature Publishing Group
Subject
/ Animals
/ Biomedical and Life Sciences
/ Cellular Senescence - drug effects
/ Down-Regulation - drug effects
/ Fibrosis
/ Humans
/ Inflammation - complications
/ Intercellular Signaling Peptides and Proteins - metabolism
/ Male
/ Mice
/ NADPH Oxidase 4 - metabolism
/ Pulmonary Fibrosis - chemically induced
/ Pulmonary Fibrosis - complications
/ Pulmonary Fibrosis - drug therapy
/ Pulmonary Fibrosis - pathology
/ Roxithromycin - therapeutic use
/ Senescence-Associated Secretory Phenotype - drug effects
/ Vaccine
